MSDC 0160

Drug Profile

MSDC 0160

Alternative Names: Mitoglitazone; MSDC-0160

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metabolic Solutions Development Company
  • Developer Metabolic Solutions Development Company; PKD Foundation; Van Andel Research Institute
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • No development reported Parkinson's disease; Polycystic kidney disease
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in USA (PO)
  • 07 Dec 2016 Van Andel Research Institute and Metabolic Solutions Development Company announce intention to initiate clinical trials for Parkinson's disease in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top